Trial Profile
Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Assess the Efficacy and Safety of Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Apr 2015
Price :
$35
*
At a glance
- Drugs Levacecarnine (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 28 Jun 2014 Status changed from active, no longer recruiting to discontinued, as per European Clinical Trials Database record.
- 20 Jun 2013 Planned end date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 20 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.